Cardiovascular Disease in HIV and Hepatitis C: Risk Outcomes After Hepatitis C Eradication

Overview

This is an interventional, non-randomized, controlled prospective study to treat HCV in mono-infected and HIV co-infected individuals and compare cardiovascular risk outcomes to HIV mono-infected controls. This pilot study will demonstrate whether functional cure of HCV reduces myocardial injury and risk of cardiovascular disease.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Non-Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Basic Science
    • Masking: None (Open Label)
  • Study Primary Completion Date: July 1, 2021

Interventions

  • Drug: Elbasvir / Grazoprevir Oral Tablet [Zepatier]
    • All approved direct-acting antivirals for hepatitis C will be used as the intervention.
  • Procedure: Cardiac MRI
    • Cardiac MRI to assess for myocardial function and fibrosis

Arms, Groups and Cohorts

  • Active Comparator: HIV Mono-Infected
    • Patients infected with HIV only, and not currently or previously infected with hepatitis C.
  • Experimental: Hepatitis C Mono-Infected
    • Patients infected with Hepatitis C and have no evidence of active HIV or hepatitis B infection
  • Experimental: HIV and Hepatitis C Co-Infected
    • Patients co-infected with HIV and hepatitis C, and have no evidence of active hepatitis B infection.

Clinical Trial Outcome Measures

Primary Measures

  • Change in cardiovascular disease risk from baseline to after functional cure of hepatitis C, as measured by high-sensitivity C-reactive protein
    • Time Frame: Baseline to 48 weeks after functional cure of HCV
    • Change in high-sensitivity C-reactive protein

Secondary Measures

  • Change in troponin I and troponin T from baseline to after functional cure of hepatitis C
    • Time Frame: Baseline to 48 weeks after functional cure of HCV
    • Change in the cardiac biomarkers Troponin I and Troponin T

Participating in This Clinical Trial

Inclusion Criteria

1. Age > or equal to 18 years old 2. Able and willing to sign informed consent 3. Chronically infected with any HCV genotype (1a, 1b, 2, 3, 4, 5, or 6), defined as any individual with documentation of positive HCV antibody and positive HCV RNA test (HCV RNA of 2,000 IU/mL or greater) 4. If HIV+, suppressed on a stable, protocol-approved, ARV regimen for ≥ 8 weeks prior to starting HCV treatment 1. HIV RNA < 50 copies/mL (or < LLOQ if the local laboratory assay's LLOQ is ≥50 copies/mL) prior to Screening. Subjects with an isolated or unconfirmed HIV RNA > 50 copies/mL (or > LLOQ if the local laboratory assay's LLOQ is ≥50 copies/mL) are not excluded. 2. CD4 count >100 cells/mm3 5. Willing to have samples stored for future use 6. If tested positive for NS5A resistance-associated polymorphisms or PEG-IFN and ribavirin experienced, able to tolerate ribavirin-containing regimen for 16 weeks. Ribavirin will be administered at the discretion of the PI. 7. Women of childbearing potential who receive ribavirin will have to be willing to commit to abstinence from sexual activity, or use of two forms of contraceptive during treatment and for the 6 months after completion of ribavirin. Men receiving ribavirin who are sexually active with women will also have to be willing to commit to abstinence from sexual activity, or use of two forms of contraceptive during treatment and for the 6 months after completion of ribavirin. Exclusion Criteria:

1. Decompensated liver disease (Childs Pugh B or C) 2. Unable to comply with research study visits 3. Poor venous access not allowing screening laboratory collection 4. Have any condition that the investigator considers a contraindication to study participation 5. Pregnant or breastfeeding woman 6. Prior HCV treatment with Direct-Acting Antivirals. Note: Patients who are treatment-experienced with PEG-IFN/RBV will not be excluded; their inclusion in the study will be considered by the PI. 7. HIV+ patients with prior HCV treatment who achieved sustained virologic response (SVR)/ functional cure 8. Use of a concomitant medication that is contraindicated with the use of the DAA for HCV treatment (per package insert) 9. Coinfection with HCV and HBV, in partcular HBsAg + patients. a. Patients with HBcAb+ will not be excluded, but will have HBV DNA levels checked and will be monitored while on DAA therapy and medically managed as considered appropriate by the PI. 10. Have any condition that the investigator considers a contraindication to study participation or not eligible per standard of care for HCV treatment 11. Patients with the following devices are excluded from participating in the cardiovascular MRI study:

  • Central nervous system aneurysm clip – Implanted neural stimulator – Implanted cardiac pacemaker or defibrillator – Cochlear implant – Ocular foreign body (e.g. metal shavings) – Implanted insulin pump – Metal shrapnel or bullet 12. The following groups of people are also excluded from participating in the cardiovascular MRI study: – Patients with stable renal disease (estimated glomerular filtration rate (eGFR)<30ml/min/1.73m2 body surface area. The eGFR must be within two weeks of the the MRI exam. – Patients with acute renal disease. 13. Patients who choose to have the cardiac MRI and are over 60 years of age, have a history of renal failure, or have type I or II diabetes mellitus must have laboratory tests the same day as the MRI exam. 14. Positive urine drug screen at screening. Not all patients with positive drug screen will be excluded; decision will be made by the PI.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 70 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • University of Maryland, Baltimore
  • Collaborator
    • National Institutes of Health (NIH)
  • Provider of Information About this Clinical Study
    • Principal Investigator: Poonam Mathur, Assistant Professor – University of Maryland, Baltimore
  • Overall Official(s)
    • Poonam Mathur, DO, Principal Investigator, University of Maryland, Baltimore
  • Overall Contact(s)
    • Rachel Silk, RN, 3013267652, rsilk@ihv.umaryland.edu

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.